Treatment of FLT3-ITD-positive acute myeloid leukemia relapsing after allogeneic stem cell transplantation with sorafenib.

[1]  N. Mounier,et al.  New sequential treatment with chemotherapy and reduced‐intensity conditioning for allogeneic stem‐cell transplantation in very high‐risk acute myeloid leukemia , 2011, American journal of hematology.

[2]  P. Thall,et al.  Clofarabine ± fludarabine with once daily i.v. busulfan as pretransplant conditioning therapy for advanced myeloid leukemia and MDS. , 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[3]  P. Chiusolo,et al.  Sorafenib for refractory FMS-like tyrosine kinase receptor-3 (FLT3/ITD+) acute myeloid leukemia after allogenic stem cell transplantation. , 2011, Leukemia research.

[4]  M. Konopleva,et al.  Phase I study of sorafenib in patients with refractory or relapsed acute leukemias , 2011, Haematologica.

[5]  Krishna Komanduri,et al.  Maintenance therapy with low‐dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome , 2010, Cancer.

[6]  P. Thall,et al.  A Phase I/II Trial of Plerixafor/G-CSF Combined with IV Bu/Flu Conditioning Regimen In AML/MDS Patients Undergoing Allogenic Stem Cell Transplantation , 2010 .

[7]  E. Estey,et al.  NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[8]  R. Childs,et al.  Toxic effects of sorafenib when given early after allogeneic hematopoietic stem cell transplantation. , 2010, Blood.

[9]  A. Mackensen,et al.  Sorafenib induces sustained molecular remission in FLT3-ITD positive AML with relapse after second allogeneic stem cell transplantation without exacerbation of acute GVHD: a case report. , 2010, Leukemia research.

[10]  A. Lebeau,et al.  Immunohistochemistry and molecular analyses in myeloid sarcoma of the breast in a patient with relapse of NPM1-mutated and FLT3-mutated AML after allogeneic stem cell transplantation , 2010, Journal of Clinical Pathology.

[11]  Kathleen M Murphy,et al.  FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML. , 2010, Blood.

[12]  M. Eilers,et al.  Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation. , 2009, Blood.

[13]  E. Estey,et al.  Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML. , 2009, Blood.

[14]  I. Bruns,et al.  Sorafenib (Nexavar) induces molecular remission and regression of extramedullary disease in a patient with FLT3-ITD+ acute myeloid leukemia. , 2009, Leukemia research.

[15]  M. Konopleva,et al.  Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia. , 2008, Journal of the National Cancer Institute.

[16]  H. Kantarjian,et al.  Potential role of sorafenib in the treatment of acute myeloid leukemia , 2008, Leukemia & lymphoma.

[17]  E. Shpall,et al.  Treatment of AML and MDS relapsing after reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation , 2007, Leukemia.

[18]  W. Hofmann,et al.  The C/EBPδ tumor suppressor is silenced by hypermethylation in acute myeloid leukemia , 2007 .

[19]  W. Hofmann,et al.  The C/EBPdelta tumor suppressor is silenced by hypermethylation in acute myeloid leukemia. , 2007, Blood.

[20]  P. Dent,et al.  Apoptosis Induced by the Kinase Inhibitor BAY 43-9006 in Human Leukemia Cells Involves Down-regulation of Mcl-1 through Inhibition of Translation* , 2005, Journal of Biological Chemistry.

[21]  G. Gores,et al.  The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006 , 2005, Oncogene.

[22]  G. Ledderose,et al.  Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  C. Bloomfield,et al.  Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  J. Griffin,et al.  The roles of FLT3 in hematopoiesis and leukemia. , 2002, Blood.

[25]  B. Löwenberg,et al.  Biological characteristics and prognosis of adult acute myeloid leukemia with internal tandem duplications in the Flt3 gene , 2000, Leukemia.

[26]  早川 文彦.  Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines , 2000 .

[27]  T. Naoe,et al.  Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. , 1999, Blood.

[28]  L. Kumar,et al.  Leukemia: management of relapse after allogeneic bone marrow transplantation. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  Morel,et al.  Toxic effects of sorafenib when given early after allogeneic hematopoietic stem cell transplantation , 2022 .